Although rapalogs are generally used to reduce the risk of tumours after transplantation [52, 53], there is a new study from 2022 questioning the effectiveness of early conversion to mTOR inhibitor-based IS regimens in reducing tumour incidence [54]. Here, MTOR is linked to neoplasm.